Advertisement

Reliability and diagnostic utility of radiographs in patients with incomplete atypical femoral fractures

  • Ulas AkgunEmail author
  • Umut Canbek
  • Nevres Hurriyet Aydogan
Scientific Article
  • 43 Downloads

Abstract

Objective

The aim of this study was to evaluate the sensitivity and specificity of radiographs in identifying incomplete atypical femoral fractures and to determine interobserver and intra-observer reliability.

Materials and methods

Anterior–posterior and lateral radiographs of 10 femurs with incomplete atypical femoral fractures confirmed using bone scintigraphy and magnetic resonance imaging, and 40 femurs without incomplete atypical femoral fractures confirmed using bone scintigraphy, were reviewed by 4 orthopedic surgeons and 4 radiology specialists. Sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were calculated to determine a diagnosis of incomplete atypical femoral fractures. Interobserver reliability was measured using Fleiss’ kappa value, and intra-observer reliability was ascertained using Cohen’s kappa statistic.

Results

Mean sensitivity, specificity, accuracy, and the positive and negative predictive values were found to be 89, 89, 89, 67, and 97% respectively, in diagnosing incomplete atypical femoral fractures using radiographs. Interobserver reliability was found to be at a good level (Fleiss’ kappa = 0.66, standard error = 0.03, 95% confidence interval = 0.61–0.71). Intra-observer Cohen’s kappa values ranged from 0.53 to 0.91.

Conclusion

The use of radiography was satisfactory in identifying incomplete atypical femoral fractures, and the level of interobserver agreement was found to be good. As radiographs are associated with low positive predictive values, an advanced imaging method should be used when an increase in femoral cortical thickness is the only contributory factor to suspicion of an incomplete atypical femoral fracture.

Keywords

Diagnostic accuracy Femoral fractures Insufficiency fractures Reliability Sensitivity and specificity 

Notes

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All of the procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

The need to obtain informed consent was waived as this research comprised a retrospective review of the medical records.

References

  1. 1.
    Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22(3):465–75.CrossRefGoogle Scholar
  2. 2.
    Fischer S, Kapinos KA, Mulcahy A, Pinto L, Hayden O, Barron R. Estimating the long-term functional burden of osteoporosis-related fractures. Osteoporos Int. 2017;28(10):2843–51.CrossRefGoogle Scholar
  3. 3.
    Hopkins RB, Tarride JE, Leslie WD, et al. Estimating the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis. Osteoporos Int. 2013;24(2):581–93.CrossRefGoogle Scholar
  4. 4.
    Cummings SR, Cosman F, Lewiecki EM, et al. Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis. J Bone Miner Res. 2017;32(1):3–10.CrossRefGoogle Scholar
  5. 5.
    Silverman S, Christiansen C. Individualizing osteoporosis therapy. Osteoporos Int. 2012;23(3):797–809.CrossRefGoogle Scholar
  6. 6.
    Pazianas M, Abrahamsen B. Safety of bisphosphonates. Bone. 2011;49(1):103–10.CrossRefGoogle Scholar
  7. 7.
    Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009;24(6):1095–102.CrossRefGoogle Scholar
  8. 8.
    Clout A, Narayanasamy N, Harris I. Trends in the incidence of atypical femoral fractures and bisphosphonate therapy. J Orthop Surg. 2016;24(1):36–40.CrossRefGoogle Scholar
  9. 9.
    Feldman F. Atypical diaphyseal femoral fractures—new aspects. Skeletal Radiol. 2012;41(1):75–81.CrossRefGoogle Scholar
  10. 10.
    Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89(3):349–53.CrossRefGoogle Scholar
  11. 11.
    Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294–301.CrossRefGoogle Scholar
  12. 12.
    Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267–94.CrossRefGoogle Scholar
  13. 13.
    Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1–23.CrossRefGoogle Scholar
  14. 14.
    Ng AC, Png MA, Chua DT, Koh JS, Howe TS. Review: epidemiology and pathophysiology of atypical femur fractures. Curr Osteoporos Rep. 2014;12(1):65–73.CrossRefGoogle Scholar
  15. 15.
    Porrino JA Jr, Kohl CA, Taljanovic M, Rogers LF. Diagnosis of proximal femoral insufficiency fractures in patients receiving bisphosphonate therapy. AJR Am J Roentgenol. 2010;194(4):1061–4.CrossRefGoogle Scholar
  16. 16.
    Dell R, Greene D. A proposal for an atypical femur fracture treatment and prevention clinical practice guideline. Osteoporos Int. 2018;29(6):1277–83.CrossRefGoogle Scholar
  17. 17.
    Adams AL, Xue F, Chantra JQ, et al. Sensitivity and specificity of radiographic characteristics in atypical femoral fractures. Osteoporos Int. 2017;28(1):413–7.CrossRefGoogle Scholar
  18. 18.
    Rosenberg ZS, La Rocca Vieira R, Chan SS, et al. Bisphosphonate-related complete atypical subtrochanteric femoral fractures: diagnostic utility of radiography. AJR Am J Roentgenol. 2011;197(4):954–60.CrossRefGoogle Scholar
  19. 19.
    Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.CrossRefGoogle Scholar
  20. 20.
    Starr J, Tay YKD, Shane E. Current understanding of epidemiology, pathophysiology, and management of atypical femur fractures. Curr Osteoporos Rep. 2018;16(4):519–29.CrossRefGoogle Scholar
  21. 21.
    Matcuk GR Jr, Mahanty SR, Skalski MR, Patel DB, White EA, Gottsegen CJ. Stress fractures: pathophysiology, clinical presentation, imaging features, and treatment options. Emerg Radiol. 2016;23(4):365–75.CrossRefGoogle Scholar
  22. 22.
    Arroll B, Schechter MT, Sheps SB. The assessment of diagnostic tests: a comparison of medical literature in 1982 and 1985. J Gen Intern Med. 1988;3(5):443–7.CrossRefGoogle Scholar
  23. 23.
    Sheps SB, Schechter MT. The assessment of diagnostic tests. A survey of current medical research. JAMA. 1984;252(17):2418–22.CrossRefGoogle Scholar
  24. 24.
    Niimi R, Kono T, Nishihara A, et al. Cortical thickness of the femur and long-term bisphosphonate use. J Bone Miner Res. 2015;30(2):225–31.CrossRefGoogle Scholar
  25. 25.
    Koeppen VA, Schilcher J, Aspenberg P. Atypical fractures do not have a thicker cortex. Osteoporos Int. 2012;23(12):2893–6.CrossRefGoogle Scholar

Copyright information

© ISS 2019

Authors and Affiliations

  • Ulas Akgun
    • 1
    Email author
  • Umut Canbek
    • 1
  • Nevres Hurriyet Aydogan
    • 1
  1. 1.Faculty of Medicine, Department of Orthopaedics and TraumatologyMugla Sitki Kocman UniversityMenteseTurkey

Personalised recommendations